Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Paxman ABFRA:B0F +0.99%82 3-Year EBITDA Growth Rate is 14.50% as of Jun. 2026, which is 59% below its 10-year median of 35.80. GuruFocus rates FRA:B0F with a GF Score™ of 82/100 and a GF Value™ of €5.63 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Paxman AB ranks better than 58.14% on this metric.
During the past 12 months, Paxman AB's average EBITDA Per Share Growth Rate was -30.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Paxman AB was 165.40% per year. The lowest was 14.50% per year. And the median was 35.80% per year.
Paxman AB (FRA:B0F) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Paxman AB 3-Year EBITDA Growth Rate Related Terms
FRA:B0F vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Paxman AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paxman AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paxman AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Paxman AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.50% mean?
Paxman AB (FRA:B0F) has a 3-Year EBITDA Growth Rate of 14.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Paxman AB and its competitors. This is 59% below median its historical median of 35.80. Over the past decade, Paxman AB's 3-Year EBITDA Growth Rate has ranged from 14.50 to 165.40. According to the industry distribution chart, Paxman AB ranks #288 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 41.9%.
Is Paxman AB's 3-Year EBITDA Growth Rate too high?
Paxman AB's current 3-Year EBITDA Growth Rate of 14.50% is 59% below median its 10-year median of 35.80. Over the past 10 years, this metric has ranged from a low of 14.50 to a high of 165.40. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. Paxman AB's value of 14.50% is 83.5% above this industry median. Based on the distribution chart, Paxman AB ranks #288 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Paxman AB has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Paxman AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Paxman AB ranks #288 out of 688 companies for 3-Year EBITDA Growth Rate. This puts Paxman AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.90. Paxman AB's value of 14.50% is 83.5% above this benchmark. Historically, Paxman AB's own 3-Year EBITDA Growth Rate has ranged from 14.50 to 165.40 over the past decade. While the company's 10-year median is 35.80 vs. the industry median of 7.90, Paxman AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paxman AB's current 3-Year EBITDA Growth Rate of 14.50% is 83.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Paxman AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paxman AB's current 3-Year EBITDA Growth Rate is 14.50%, which is 59% below median its own 10-year median of 35.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paxman AB stock overvalued right now?
Based on GuruFocus' analysis, Paxman AB (FRA:B0F) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.63, compared to a current price of €5.09 — trading 9.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 14.50%, which is 59% below median its 10-year median of 35.80 and 83.5% above the Medical Devices & Instruments industry median of 7.90. Paxman AB's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Paxman AB (FRA:B0F), the current 3-Year EBITDA Growth Rate is 14.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paxman AB (FRA:B0F) Overvalued in 2026?
Based on GuruFocus' analysis, Paxman AB stock appears to be undervalued.
The current stock price of €5.09 is trading 9.6% below its estimated GF Value™ of €5.63.
GuruFocus considers Paxman AB to be Modestly Undervalued.
Key valuation signals for FRA:B0F:
3-Year EBITDA Growth Rate: 14.50% (59% below median its 10-year median of 35.80)
GF Value™: €5.63 vs. price of €5.09 (9.6% below fair value)
Industry Position: 83.5% above the Medical Devices & Instruments median (#288 of 688)
No single metric tells the full story. See the FRA:B0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paxman AB is a Sweden-based company engaged in the development of the PAXMAN Scalp Cooling System, which has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The portfolio includes both the Paxman and Digni Capsystems with several installations in hospitals, clinics, and treatment centres world-wide.
82GF Score
Get the complete analysis for FRA:B0F
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:B0F has been successfully added to your 
